Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
CA 2369200 A1 · Owner: The Government Of The United States Of America · Inventors: Whitehead, Stephen S.; Murphy, Brian R.; Collins, Peter L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Chimeric respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing one or more heterologous gene(s) or gene segment(s) from one RSV subgroup or strain into a recipient RSV background of a different subgroup or strain. The resulting chimeric RSV virus or subviral particle is infectious and attenuated, preferably by introduction of selected mutations specifying attenuated phenotypes into a chimeric genome or antigenome to yield, for example, temperature sensitive (ts) and/or cold adapted (ca) vaccine strains. Alternatively chimeric RSV and vaccine , compositions thereof incorporate other mutations specifying desired structural and/or phenotypic …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 31, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 31, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 31, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.